Details for Patent: 9,023,878

Title:	2-iminobiotin formulations and uses thereof
Abstract:	The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the invention pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from said administration.
Inventor(s):	Leufkens; Paul W. T. J. ('s-Hertogenbosch, NL)
Assignee:	Neurophyxia B.V. ('S-Hertogenbosch, NL)
Filing Date:	May 26, 2011
Application Number:	13/700,090
Claims:	1. An aqueous, soluble formulation of 2-iminobiotin, having a pH between around 3 and around 7, and comprising 0.75 mg or more of 2-iminobiotin and at least 1 mM citric acid, citrate or a mixture of citric acid and citrate. 2. The formulation of claim 1, comprising at least 20 mM of citric acid, citrate, or a mixture of citric acid and citrate. 3. A method of treating perinatal asphyxia in a neonate, the method comprising: utilizing the formulation of claim 1 to treat the neonate. 4. The method according to claim 3, wherein the formulation is administered to the neonate's mother prior to and/or during labor. 5. The method according to claim 4, further comprising: subjecting the neonate to hypotheimia. 6. The method of claim 3, wherein the formulation is administered to the neonate's mother prior to and/or during labor. 7. The method according to claim 3, further comprising: subjecting the neonate to hypothermia. 8. A method of treating a neonate for complications associated with childbirth, the method comprising: administering the formulation of claim 1 to the neonate to treat the effects of complications during childbirth. 9. The method according to claim 8, further comprising: subjecting the neonate to hypothermia. 10. A method of treating a neonate for perinatal asphyxia, the method comprising: administering the formulation of claim 1 to the neonate to treat the perinatal asphyxia, and subjecting the neonate to hypothermia. 11. An aqueous, soluble formulation of 2-iminobiotin, having a pH between 3 and 6, and comprising between 0.5 mg/ml and 5 mg/ml of 2-iminobiotin and at least 1 mM citric acid, citrate or a mixture of citric acid and citrate. 12. The formulation of claim 11, wherein the citric acid, citrate, or mixture of citric acid and citrate is present at a concentration of between 10 mM and 20 mM. 13. An aqueous, soluble formulation of 2-iminobiotin, having a pH between 3 and 7, and comprising: between 0.5 mg/ml to 10 mg/ml of 2-iminobiotin and at least 1 mM citric acid, citrate, or a mixture of citric acid and citrate. 14. The formulation of claim 13 further comprising: between around 2.5 to around 40% of a substituted beta-cyclodextrin.